Literature DB >> 33644056

Long Non-coding RNA Expression Patterns in Stomach Adenocarcinoma Serve as an Indicator of Tumor Mutation Burden and Are Associated With Tumor-Infiltrating Lymphocytes and Microsatellite Instability.

Dongdong Yang1, Jinling Yu2, Bing Han3, Yue Sun3, Steven Mo4,5, Jing Hu3.   

Abstract

Long non-coding RNAs (lncRNAs) are crucial in controlling important aspects of tumor immunity. However, whether the expression pattern of lncRNAs in stomach adenocarcinoma (STAD) reflects tumor immunity is not fully understood. We screened differentially expressed lncRNAs (DElncRNAs) between high and low tumor mutation burden (TMB) STAD samples. Using the least absolute shrinkage and selection operator method, 33 DElncRNAs were chosen to establish a lncRNA-based signature classifier for predicting TMB levels. The accuracy of the 33-lncRNA-based signature classifier was 0.970 in the training set and 0.950 in the test set, suggesting the expression patterns of the 33 lncRNAs may be an indicator of TMB in STAD. Survival analysis showed that a lower classifier index reflected better prognosis for STAD patients, and the index showed correlation with expression of immune checkpoint molecules (PD1, PDL1, and CTLA4), tumor-infiltrating lymphocytes, and microsatellite instability. In conclusion, STAD samples with different tumor mutation burdens have different lncRNA expression patterns. The 33-lncRNA-based signature classifier index may be an indicator of TMB and is associated expression of immune checkpoints, tumor-infiltrating lymphocytes, and microsatellite instability.
Copyright © 2021 Yang, Yu, Han, Sun, Mo and Hu.

Entities:  

Keywords:  immune checkpoint molecules; lncRNAs; stomach adenocarcinoma; the Cancer Genome Atlas; tumor immunity

Year:  2021        PMID: 33644056      PMCID: PMC7907456          DOI: 10.3389/fcell.2021.618313

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  49 in total

1.  First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Authors:  David P Carbone; Martin Reck; Luis Paz-Ares; Benjamin Creelan; Leora Horn; Martin Steins; Enriqueta Felip; Michel M van den Heuvel; Tudor-Eliade Ciuleanu; Firas Badin; Neal Ready; T Jeroen N Hiltermann; Suresh Nair; Rosalyn Juergens; Solange Peters; Elisa Minenza; John M Wrangle; Delvys Rodriguez-Abreu; Hossein Borghaei; George R Blumenschein; Liza C Villaruz; Libor Havel; Jana Krejci; Jesus Corral Jaime; Han Chang; William J Geese; Prabhu Bhagavatheeswaran; Allen C Chen; Mark A Socinski
Journal:  N Engl J Med       Date:  2017-06-22       Impact factor: 91.245

2.  EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.

Authors:  Jin-Yuan Shih; Chien-Hung Gow; Pan-Chyr Yang
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

3.  New window of opportunity with ICIs in melanoma.

Authors:  David Killock
Journal:  Nat Rev Clin Oncol       Date:  2018-12       Impact factor: 66.675

4.  Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.

Authors:  Yi Xiao; Ding Ma; Shen Zhao; Chen Suo; Jinxiu Shi; Meng-Zhu Xue; Miao Ruan; Hai Wang; Jingjing Zhao; Qin Li; Peng Wang; Leming Shi; Wen-Tao Yang; Wei Huang; Xin Hu; Ke-Da Yu; Shenglin Huang; François Bertucci; Yi-Zhou Jiang; Zhi-Ming Shao
Journal:  Clin Cancer Res       Date:  2019-03-05       Impact factor: 12.531

5.  The Molecular Signatures Database (MSigDB) hallmark gene set collection.

Authors:  Arthur Liberzon; Chet Birger; Helga Thorvaldsdóttir; Mahmoud Ghandi; Jill P Mesirov; Pablo Tamayo
Journal:  Cell Syst       Date:  2015-12-23       Impact factor: 10.304

6.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Authors:  Hira Rizvi; Francisco Sanchez-Vega; Konnor La; Walid Chatila; Philip Jonsson; Darragh Halpenny; Andrew Plodkowski; Niamh Long; Jennifer L Sauter; Natasha Rekhtman; Travis Hollmann; Kurt A Schalper; Justin F Gainor; Ronglai Shen; Ai Ni; Kathryn C Arbour; Taha Merghoub; Jedd Wolchok; Alexandra Snyder; Jamie E Chaft; Mark G Kris; Charles M Rudin; Nicholas D Socci; Michael F Berger; Barry S Taylor; Ahmet Zehir; David B Solit; Maria E Arcila; Marc Ladanyi; Gregory J Riely; Nikolaus Schultz; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2018-01-16       Impact factor: 44.544

Review 7.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

8.  Robust enumeration of cell subsets from tissue expression profiles.

Authors:  Aaron M Newman; Chih Long Liu; Michael R Green; Andrew J Gentles; Weiguo Feng; Yue Xu; Chuong D Hoang; Maximilian Diehn; Ash A Alizadeh
Journal:  Nat Methods       Date:  2015-03-30       Impact factor: 28.547

9.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data.

Authors:  Antonio Colaprico; Tiago C Silva; Catharina Olsen; Luciano Garofano; Claudia Cava; Davide Garolini; Thais S Sabedot; Tathiane M Malta; Stefano M Pagnotta; Isabella Castiglioni; Michele Ceccarelli; Gianluca Bontempi; Houtan Noushmehr
Journal:  Nucleic Acids Res       Date:  2015-12-23       Impact factor: 16.971

10.  Maftools: efficient and comprehensive analysis of somatic variants in cancer.

Authors:  Anand Mayakonda; De-Chen Lin; Yassen Assenov; Christoph Plass; H Phillip Koeffler
Journal:  Genome Res       Date:  2018-10-19       Impact factor: 9.043

View more
  4 in total

1.  MZF1 Transcriptionally Activated MicroRNA-328-3p Suppresses the Malignancy of Stomach Adenocarcinoma via Inhibiting CD44.

Authors:  Zining Qi; Jing Wang; Yaoping Li; Yanzhao Xu
Journal:  J Immunol Res       Date:  2022-05-28       Impact factor: 4.493

2.  Predicting the Survival and Immune Landscape of Colorectal Cancer Patients Using an Immune-Related lncRNA Pair Model.

Authors:  Chao Ma; Xin Zhang; Xudong Zhao; Nan Zhang; Sixin Zhou; Yonghui Zhang; Peiyu Li
Journal:  Front Genet       Date:  2021-09-06       Impact factor: 4.599

Review 3.  Targeting non-coding RNAs to overcome cancer therapy resistance.

Authors:  BaoQing Chen; Mihnea P Dragomir; Chen Yang; Qiaoqiao Li; David Horst; George A Calin
Journal:  Signal Transduct Target Ther       Date:  2022-04-13

4.  Mutator-Derived lncRNA Landscape: A Novel Insight Into the Genomic Instability of Prostate Cancer.

Authors:  Liansha Tang; Wanjiang Li; Hang Xu; Xiaonan Zheng; Shi Qiu; Wenbo He; Qiang Wei; Jianzhong Ai; Lu Yang; Jiyan Liu
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.